glp-1 receptor agonist with dpp-4 inhibitor combination not recommended It's the first in a class of drugs called inhibitors Frontiers | DPP-4 inhibitors for
Description
Relative liver fat loss of approximately 27% to 36% is noted for the treatment groups, compared to a gain of 5% in the placebo group

Heres what you need to know about GLP-1 Agonists

doi: 10.1111/j.1463-1326.2010.01355.x

We want people who need these medications to be able to access them, he said
This severely biased the study population such that the true risk of developing NAION is likely much lower in a general population

And it actually has been very effective with fatty liver
00171-7/asset/ac74d262-e278-41b2-8d5c-af3229a7e170/main.assets/gr1.jpg)